EP3317246A4 - Conjugaison spécifique d'une molécule de liaison cellulaire - Google Patents

Conjugaison spécifique d'une molécule de liaison cellulaire Download PDF

Info

Publication number
EP3317246A4
EP3317246A4 EP15772625.8A EP15772625A EP3317246A4 EP 3317246 A4 EP3317246 A4 EP 3317246A4 EP 15772625 A EP15772625 A EP 15772625A EP 3317246 A4 EP3317246 A4 EP 3317246A4
Authority
EP
European Patent Office
Prior art keywords
cell
binding molecule
specific conjugation
conjugation
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP15772625.8A
Other languages
German (de)
English (en)
Other versions
EP3317246A2 (fr
Inventor
Robert Yongxin Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sushou M conj Biotech Co Ltd
Original Assignee
Sushou M conj Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sushou M conj Biotech Co Ltd filed Critical Sushou M conj Biotech Co Ltd
Publication of EP3317246A2 publication Critical patent/EP3317246A2/fr
Publication of EP3317246A4 publication Critical patent/EP3317246A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/20—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
EP15772625.8A 2015-07-04 2015-07-04 Conjugaison spécifique d'une molécule de liaison cellulaire Pending EP3317246A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2015/055051 WO2015151080A2 (fr) 2015-07-04 2015-07-04 Conjugaison spécifique d'une molécule de liaison cellulaire

Publications (2)

Publication Number Publication Date
EP3317246A2 EP3317246A2 (fr) 2018-05-09
EP3317246A4 true EP3317246A4 (fr) 2019-02-27

Family

ID=54241397

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15772625.8A Pending EP3317246A4 (fr) 2015-07-04 2015-07-04 Conjugaison spécifique d'une molécule de liaison cellulaire

Country Status (5)

Country Link
EP (1) EP3317246A4 (fr)
JP (1) JP6700321B2 (fr)
CN (2) CN113698335A (fr)
CA (1) CA2991384C (fr)
WO (1) WO2015151080A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2974651A1 (fr) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Polytherapie anticancereuse a base de smc
EP3160513B1 (fr) 2014-06-30 2020-02-12 Glykos Finland Oy Dérivé de saccharide d'une charge utile toxique et conjugués d'anticorps de celui-ci
JP7330515B2 (ja) * 2015-08-10 2023-08-22 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 新規な連結体及び生体分子と薬物との特異的共役におけるその使用
WO2015155753A2 (fr) * 2015-08-10 2015-10-15 Suzhou M-Conj Biotech Co., Ltd Nouvelles séquences de liaison et leurs utilisation pour la conjugaison spécifique de médicaments à une molécule biologique
SG11201806594QA (en) 2016-02-04 2018-09-27 Suzhou M Conj Biotech Co Ltd Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2018009916A1 (fr) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Conjugués d'adjuvant d'anticorps
CN106474147B (zh) * 2016-10-14 2022-07-05 上海颉隆投资管理有限公司 一种预防和控制人***状瘤病毒感染的敷料及其制备方法
KR20220147720A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN109444349B (zh) * 2018-12-26 2020-07-07 中国科学院地球化学研究所 一种测定室内植物代谢水利用份额和实际需水量的方法
WO2020190725A1 (fr) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugués ciblant le her2
CN111773183B (zh) * 2019-04-04 2022-02-01 沈阳药科大学 一种Cu(DDC)2纳米核脂质体及其制备方法和应用
WO2020232119A1 (fr) 2019-05-14 2020-11-19 Nuvation Bio Inc. Composés ciblant des récepteurs hormonaux nucléaires anticancéreux
EP3991752A4 (fr) 2019-06-29 2023-03-29 Hangzhou Dac Biotech Co., Ltd Conjugué molécule de liaison cellulaire-dérivé de tubulysine et méthode de préparation associée
CN110308145A (zh) * 2019-07-10 2019-10-08 迪瑞医疗科技股份有限公司 一种沙眼衣原体糖原检测试剂、沙眼衣原体糖原检测试纸条及其制备方法
CN112341521B (zh) * 2019-08-09 2024-06-25 上海翰森生物医药科技有限公司 一种小分子活性化合物及其抗体偶联物、其制备方法和医药用途
WO2021097046A1 (fr) 2019-11-13 2021-05-20 Nuvation Bio Inc. Composés ciblant des récepteurs hormonaux nucléaires anticancéreux
CN110835405B (zh) * 2019-11-28 2020-09-15 安阳师范学院 用于肿瘤检测的高分子生物传感器及制备方法及应用
CN111879684B (zh) * 2020-06-18 2021-12-21 山东大学 一种基于流式细胞术的吞噬细胞功能检测方法
CN113925973A (zh) * 2020-07-14 2022-01-14 辽宁中健医药科技有限公司 一种多肽偶联药物及其制备方法和应用
CN112409242B (zh) * 2020-09-25 2022-07-12 华南农业大学 一种氨氯地平半抗原、人工抗原、抗体及其制备方法和应用
CN112379029B (zh) * 2020-11-10 2022-03-08 苏州艾迪迈医疗科技有限公司 一种检测血液中抗新型冠状病毒药物浓度的方法
CA3211696A1 (fr) * 2021-02-23 2022-09-01 Children's Medical Center Corporation Conjugue medicament-anticorps de molecule d'adhesion intercellulaire 1 (icam1) et ses utilisations
TW202304928A (zh) 2021-03-23 2023-02-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
CN113214403B (zh) * 2021-04-25 2023-06-09 重庆威斯腾前沿生物研究院有限责任公司 一种链霉亲和素磁珠及其制备方法
IL308104A (en) 2021-05-03 2023-12-01 Nuvation Bio Inc Nuclear hormone receptor-targeted compounds against cancer
CN113913535A (zh) * 2021-11-30 2022-01-11 江西农业大学 一种用于鉴别蓝孔雀白羽性状的因果基因及其应用
WO2023125349A1 (fr) * 2021-12-27 2023-07-06 山东先声生物制药有限公司 Anticorps anti-gucy2c et son application
CN116239513B (zh) * 2023-05-05 2023-08-18 天津凯莱英制药有限公司 Mmae关键中间体的制备方法、mmae的制备方法和抗体偶联药物
CN116813710A (zh) * 2023-07-05 2023-09-29 重庆药友制药有限责任公司 一种卡非佐米的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101723961A (zh) * 2009-12-08 2010-06-09 刘超美 一种β-内酰胺类双抗生素化合物及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228358D0 (en) * 2002-12-05 2003-01-08 Unilever Plc Improvements relating to fabric treatment
UA108598C2 (xx) * 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
EP2610263A1 (fr) * 2011-12-30 2013-07-03 Brossmer, Reinhard Dimères d'acide sialique
US10131682B2 (en) * 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
CN103933575B (zh) * 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
US11229711B2 (en) * 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
AU2013399485B2 (en) * 2013-09-02 2019-07-25 Hangzhou Dac Biotech Co., Ltd Novel cytotoxic agents for conjugation of drugs to cell binding molecule
CN103467590B (zh) * 2013-09-02 2016-04-13 深圳大学 生物偶联体、制备其的嘌呤类化合物、合成方法、药用制剂以及其在免疫调节中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101723961A (zh) * 2009-12-08 2010-06-09 刘超美 一种β-内酰胺类双抗生素化合物及其制备方法和用途

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A. S. HASHMI: "Photochemical Synthesis of Prochiral Dialkyl 3,3-Dialkylcyclopropene-1,2- dicarboxylates with Facial Shielding Substituents and Related Substrates", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 26 November 2001 (2001-11-26), GB, pages 4705 - 4732, XP055450906, ISBN: 978-0-08-097742-3 *
DIRK HEYL ET AL: "Facile Direct Synthesis of Acetylenedicarboxamides", SYNTHESIS, vol. 46, no. 11, 17 March 2014 (2014-03-17), STUTTGART, DE., pages 1463 - 1468, XP055450898, ISSN: 0039-7881, DOI: 10.1055/s-0033-1341101 *
GRETE VAN WUYTSWINKEL ET AL: "A convergent synthesis of heterocyclic dendrimers using the 1,3-dipolar cycloaddition reaction of organic azides and acetylenedicarboxylate esters", ROYAL CHEMICAL SOCIETY. JOURNAL. PERKIN TRANSACTIONS 1, vol. 1, no. 9, 1 January 2000 (2000-01-01), GB, pages 1337 - 1340, XP055450907, ISSN: 1470-4358, DOI: 10.1039/b000025f *
J. L. CHARLTON: "'Synthesis of chiral Esters of Acetylenedicarboxylic Acid'", TETRAHEDRON LETTERS, vol. 35, no. 34, 22 August 1994 (1994-08-22), pages 6243 - 6246, XP055450908 *
JOÃO P. M. NUNES ET AL: "Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody-drug conjugate (ADC)", CHEMICAL COMMUNICATIONS, vol. 51, no. 53, 1 January 2015 (2015-01-01), pages 10624 - 10627, XP055539726, ISSN: 1359-7345, DOI: 10.1039/C5CC03557K *
JOHN A. MIKROYANNIDIS ET AL: "Synthesis, photophysics, structure-tunable photoluminescence, and electrochemical properties of soluble poly(p-phenylenevinylene)-based polymers with adjacent 1,3,4-oxadiazoles in the backbone", JOURNAL OF POLYMER SCIENCE, PART A: POLYMER CHEMISTRY, vol. 43, no. 14, 1 January 2005 (2005-01-01), US, pages 3079 - 3090, XP055450904, ISSN: 0887-624X, DOI: 10.1002/pola.20771 *
LOURDES CASTAÑEDA ET AL: "Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation", CHEMICAL COMMUNICATIONS, vol. 49, no. 74, 1 January 2013 (2013-01-01), pages 8187 - 8189, XP055539224, ISSN: 1359-7345, DOI: 10.1039/c3cc45220d *
RAVI V. J. CHARI ET AL: "Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 53, no. 15, 7 April 2014 (2014-04-07), pages 3796 - 3827, XP055167825, ISSN: 1433-7851, DOI: 10.1002/anie.201307628 *

Also Published As

Publication number Publication date
CN108811499A (zh) 2018-11-13
JP2018523639A (ja) 2018-08-23
CA2991384A1 (fr) 2015-10-08
EP3317246A2 (fr) 2018-05-09
CN113698335A (zh) 2021-11-26
WO2015151080A2 (fr) 2015-10-08
JP6700321B2 (ja) 2020-05-27
CA2991384C (fr) 2022-11-08
CN108811499B (zh) 2021-09-24
WO2015151080A3 (fr) 2016-06-02

Similar Documents

Publication Publication Date Title
EP3317246A4 (fr) Conjugaison spécifique d'une molécule de liaison cellulaire
EP3313857A4 (fr) Conjugués polymère-cyclodextrine-lipide
EP3297649A4 (fr) Conjugués peptides/oligonucléotides
EP3206710A4 (fr) Conjugués d'insuline-incrétines
EP3319936A4 (fr) Lieux de pontage pour la conjugaison des molécules de liaison cellulaire
EP3119885A4 (fr) Conjugués anticorps-fynomer
EP3137114B8 (fr) Conjugués médicament-anticorps anti-ptk7
EP3135358A4 (fr) Toupie
EP3129357A4 (fr) Conjugués de médicament et d'élément d'affinité
EP3368033A4 (fr) Composition thérapeutique à base de miel et de cannabinoïde
EP3448417A4 (fr) Conjugués dimères d'insuline-incrétine
EP3388125A4 (fr) Jouet de tir
EP3302439A4 (fr) Composition thérapeutique
EP3525808A4 (fr) Conjugués anticorps-polymère-médicament
EP3220961A4 (fr) Conjugués de vitamine d thérapeutiques
EP3152223A4 (fr) Conjugués peptide-médicament
EP3703681A4 (fr) Imipridones pour gliomes
EP3268336A4 (fr) Propergols solides pour fusées
EP3261678B8 (fr) Conjugués anticorps-uréase pour des fins thérapeutiques
EP3430033A4 (fr) Conjugués d'insuline-incrétine
EP3496755A4 (fr) Conjugués d'antagonistes de tgf- .
EP3316885A4 (fr) Immunoconjugués d'anticorps sn-38 avec un lieur cl2a
EP3001833A4 (fr) Purification de conjugués nanoparticules-anticorps
EP3127915A4 (fr) Molécule de ciblage et son utilisation
EP3347042A4 (fr) Conjugués de ppv multivalents

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180201

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07C0059760000

Ipc: A61K0047680000

A4 Supplementary search report drawn up and despatched

Effective date: 20190124

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/00 20060101ALI20190118BHEP

Ipc: C07K 16/28 20060101ALI20190118BHEP

Ipc: A61P 35/00 20060101ALI20190118BHEP

Ipc: C07C 237/52 20060101ALI20190118BHEP

Ipc: C07D 207/46 20060101ALI20190118BHEP

Ipc: A61P 37/00 20060101ALI20190118BHEP

Ipc: C07C 59/76 20060101ALI20190118BHEP

Ipc: C07D 417/14 20060101ALI20190118BHEP

Ipc: A61K 47/68 20170101AFI20190118BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200914

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516